Home Industry Reports Custom Research Blogs About Us Contact us

Biomarker Discovery Outsourcing Services Market Size & Share, By Type (Predictive, Prognostic, Safety, Surrogate Endpoints), Service (Genomics, Proteomics, Bioinformatics), Therapeutic Area (Oncology, Cardiology, Cardiovascular), End-use, Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Report ID: FBI 6221

|

Published Date: Aug-2024

|

Format : PDF, Excel

Market Outlook:

Biomarker Discovery Outsourcing Services Market surpassed USD 11.51 Billion in 2023 and is expected to exceed USD 34.03 Billion by end of the year 2032, observing around 12.8% CAGR between 2024 and 2032.

Base Year Value (2023)

USD 11.51 Billion

19-23 x.x %
24-32 x.x %

CAGR (2024-2032)

12.8%

19-23 x.x %
24-32 x.x %

Forecast Year Value (2032)

USD 34.03 Billion

19-23 x.x %
24-32 x.x %
Biomarker Discovery Outsourcing Services Market

Historical Data Period

2019-2023

Biomarker Discovery Outsourcing Services Market

Largest Region

North America

Biomarker Discovery Outsourcing Services Market

Forecast Period

2024-2032

Get more details on this report -

Market Dynamics:

Growth Drivers & Opportunity:

The Biomarker Discovery Outsourcing Services Market is expected to witness significant growth in the coming years due to the increasing demand for personalized medicine and targeted therapies. This is driven by the growing prevalence of chronic diseases such as cancer and cardiovascular diseases, which require a more personalized approach to treatment. Additionally, advancements in technology, such as genomics and proteomics, are driving the demand for biomarker discovery outsourcing services as companies seek to leverage these tools for drug development and clinical research.

Report Scope

Report CoverageDetails
Segments CoveredType, Service, Therapeutic Area, End-Use
Regions Covered• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company ProfiledBio-Rad Laboratories,, Parexel International (MA), Svar Life Science, Sino Biological, Inc, ICON plc., Integrated DNA Technologies,, Almac Group Limited, REPROCELL, Frontage Labs, Biomcare ApS, Crown Bioscience, RayBiotech,, Excelra, Evotec

Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!

Industry Restraints:

The Biomarker Discovery Outsourcing Services Market may face challenges in terms of data security and regulatory compliance. As biomarker data becomes increasingly valuable and sensitive, companies outsourcing biomarker discovery services must ensure that data protection measures are in place to prevent breaches and unauthorized access. Furthermore, the regulatory landscape for biomarker discovery services is complex and evolving, leading to uncertainties and potential delays in project timelines. These factors could act as restraints for market growth in the coming years.

Regional Forecast:

Biomarker Discovery Outsourcing Services Market

Largest Region

North America

12.4% CAGR through 2032

Get more details on this report -

North America (U.S., Canada)

The biomarker discovery outsourcing services market in North America is expected to witness significant growth due to the presence of a well-established healthcare infrastructure, increasing R&D activities, and growing investments in personalized medicine. The United States is a key market in the region, with major pharmaceutical and biotechnology companies outsourcing biomarker discovery services to reduce costs and accelerate drug development processes. Canada is also experiencing growth in the biomarker discovery outsourcing services market, driven by a rise in government initiatives supporting research and development activities.

Asia Pacific (China, Japan, South Korea)

Asia Pacific is emerging as a promising region for the biomarker discovery outsourcing services market, with countries like China, Japan, and South Korea playing a key role in driving growth. China is witnessing considerable growth in the market, attributed to a rapidly expanding healthcare sector, increasing investments in biotechnology research, and rise in outsourcing activities by pharmaceutical companies. Japan and South Korea are also significant markets in the region, with a focus on precision medicine and advancements in biomarker discovery technologies.

Europe (United Kingdom, Germany, France)

Europe boasts a mature biomarker discovery outsourcing services market, with countries like the United Kingdom, Germany, and France leading the way. The United Kingdom is a hub for clinical research and biomarker discovery, supported by a strong academic and industrial base. Germany is another key market in Europe, known for its advanced healthcare infrastructure and large pharmaceutical companies outsourcing biomarker discovery services. France is also witnessing growth in the biomarker discovery outsourcing services market, driven by government initiatives promoting precision medicine and biomarker-based diagnostics.

Report Coverage & Deliverables

Historical Statistics Growth Forecasts Latest Trends & Innovations Market Segmentation Regional Opportunities Competitive Landscape
Biomarker Discovery Outsourcing Services Market
Biomarker Discovery Outsourcing Services Market

Segmentation Analysis:

""

In terms of segmentation, the global Biomarker Discovery Outsourcing Services market is analyzed on the basis of Type, Service, Therapeutic Area, End-Use.

Type:

The biomarker discovery outsourcing services market can be segmented by type into predictive, prognostic, safety, and surrogate endpoints. Predictive biomarkers are used to identify patients who are most likely to benefit from a specific treatment. Prognostic biomarkers help predict the outcome of a disease or treatment. Safety biomarkers are used to monitor the safety and toxicity of a drug. Surrogate endpoints are used as substitutes for clinical endpoints in clinical trials.

Service:

The market can also be segmented by service into genomics, proteomics, and bioinformatics. Genomics involves studying the complete set of DNA in an organism. Proteomics focuses on the study of proteins and their functions. Bioinformatics combines biology, computer science, and information technology to analyze and interpret biological data.

Therapeutic Area:

In terms of therapeutic area, the biomarker discovery outsourcing services market can be segmented into oncology, cardiology, and cardiovascular. Oncology biomarkers are used for cancer diagnosis, prognosis, and treatment selection. Cardiology biomarkers are used for diagnosing and monitoring heart conditions. Cardiovascular biomarkers are used to assess the risk of cardiovascular diseases.

End-use:

The end-use segment of the market includes pharmaceutical and biotechnology companies, academic research institutes, and contract research organizations. Pharmaceutical and biotechnology companies are the largest end-users of biomarker discovery outsourcing services, as they rely on these services for drug development and personalized medicine. Academic research institutes also utilize these services for research purposes. Contract research organizations offer biomarker discovery services to both pharmaceutical companies and academic institutions.

Get more details on this report -

Competitive Landscape:

The competitive landscape in the Biomarker Discovery Outsourcing Services Market is characterized by a diverse range of companies specializing in various aspects of biomarker identification and validation. Key players are investing heavily in advanced technologies such as genomics, proteomics, and metabolomics to enhance their service offerings. Additionally, collaborations between biotechnology firms and research institutions are becoming increasingly common, driving innovation and improving the speed of biomarker discovery. The market is witnessing significant mergers and acquisitions, enabling companies to expand their capabilities and market reach. As the demand for personalized medicine continues to rise, firms are focusing on developing efficient and cost-effective solutions to cater to the evolving needs of pharmaceutical and biotechnology customers.

Top Market Players

- Thermo Fisher Scientific

- Q2 Solutions

- Covance Inc.

- LabCorp

- Charles River Laboratories

- Eppendorf AG

- BioReference Laboratories

- Genentech

- PerkinElmer Inc.

- WuXi AppTec

Our Clients

Why Choose Us

Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.

Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.

Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.

Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.

Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.

Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.

Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.

Select Licence Type

Single User

US$ 4250

Multi User

US$ 5050

Corporate User

US$ 6150

Biomarker Discovery Outsourcing Services Market Si...

RD Code : 24